We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Haloperidol vs. Risperidone in the Treatment of Aggression in Psychotic Inmates

This study has been terminated.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00203775
First Posted: September 20, 2005
Last Update Posted: October 13, 2006
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Janssen Pharmaceutica N.V., Belgium
Information provided by:
UConn Health
  Purpose
This study examines the efficacy of haldol versus risperdal in the treatment of aggression in psychotic prison inmates. It is hypothsized that risperdal will be more effective in decreasing aggression than haldol.

Condition Intervention
Psychosis Aggression Drug: risperidone

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Efficacy of Risperidone Versus Haloperidol in the Treatment of Aggression and Hostility in Psychotic Inmates

Resource links provided by NLM:


Further study details as provided by UConn Health:

Study Start Date: July 2002
Estimated Study Completion Date: April 2004
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:age 18 or over, psychotic disorder diagnosed on SCID, inmate at correctional facility for at least 2 weeks -

Exclusion Criteria: active withdrawal from substances of abuse, non-psychotic individuals, pregnant women, people unable to give informed consent, patients on mood stabilizers

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00203775


Locations
United States, Connecticut
University of connecticut health center
Farmington, Connecticut, United States, 06030
Sponsors and Collaborators
University of Connecticut
Janssen Pharmaceutica N.V., Belgium
Investigators
Principal Investigator: catherine f lewis, md UConn Health
  More Information

ClinicalTrials.gov Identifier: NCT00203775     History of Changes
Other Study ID Numbers: RIS-USA-269
IRB Project Number 01-250
RIS-USA-T255
First Submitted: September 12, 2005
First Posted: September 20, 2005
Last Update Posted: October 13, 2006
Last Verified: May 2005

Additional relevant MeSH terms:
Aggression
Behavioral Symptoms
Risperidone
Haloperidol
Haloperidol decanoate
Serotonin Antagonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Dopamine Antagonists
Dopamine Agents
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Gastrointestinal Agents
Anti-Dyskinesia Agents